In particular, KRAS G12C-mutated NSCLC cases exhibit significantly higher rates of STK11 (20.59% versus 5.95%) and KEAP1 (15.38% versus 4.61%) alterations compared to other KRAS variants [8]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.